Metabolic
Cagrilintide
Cagrilintide (long-acting amylin analog)
Cagrilintide is an acylated analog of human amylin, the peptide co-secreted with insulin from pancreatic β-cells. It acts at the calcitonin receptor and amylin receptor subtypes, a pathway entirely separate from GLP-1 and GIP signaling. Research interest centers on whether amylin and incretin pathways are additive, which is why it appears frequently in combination studies alongside semaglutide.
Research applications
- Amylin and calcitonin receptor binding studies
- Combination pharmacology with incretin agonists
- Satiety signaling research in preclinical models
- Gastric emptying rate assays
Storage
Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days.
Reconstitution
Reconstitute with bacteriostatic water down the vial wall. Swirl gently; do not shake.
Published literature
112 papers indexed on PubMed for Cagrilintide. Showing 6, reviews first.
- 01Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son JW et al. · Endocr Rev · 2026
- 02Weight management treatment in obesity
Rubio-Herrera MA, Mera-Carreiro S · Med Clin (Barc) · 2025
- 03Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
Dutta D et al. · Indian J Endocrinol Metab · 2024
- 04Amylin analogs for the treatment of obesity without diabetes: present and future
Panou T et al. · Expert Rev Clin Pharmacol · 2024
- 05
- 06Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT et al. · N Engl J Med · 2025
Indexed from PubMed, 2026-07-19. We link to sources rather than reproducing them.
Related compounds
Semaglutide
5–20mg · COA published
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
- CAS
- 910463-68-2
- MW
- 4113.58
- Purity
- Per published certificate
Tirzepatide
10–30mg · COA published
Dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity.
- CAS
- 2023788-19-2
- MW
- 4813.45
- Purity
- Per published certificate
Retatrutide
10–30mg · COA published
Triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research.
- CAS
- 2381089-83-2
- MW
- 4731.32
- Purity
- Per published certificate
AOD-9604
5mg · COA published
C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.
- CAS
- 221231-10-3
- MW
- 1815.08
- Purity
- Per published certificate
How Cagrilintide compares
Side-by-side against the compounds researchers most often weigh it against, with price per milligram, mechanism and the published certificate for each.
Cagrilintide
From $99